Skip to main content
SpringerLink
Log in

Effects of high-dose troglitazone on insulin sensitivity and β-cell function in watanabe heritable hyperlipidemic rabbits

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

To clarify the dose-response effects of troglitazone on insulin sensitivity and β-cell function, we examined the effects of high-dose troglitazone (100 mg/day per animal, administered as a food admixture) on glucose and insulin metabolism in hyperinsulinemic Watanabe heritable hyperlipidemic (WHHL) rabbits, and compared the results with our previous results with low-dose troglitazone (10 mg/day per animal). Materials and Methods: Glucose and insulin metabolism were quantitatively characterized by a minimal model technique as reported previously. Results: When troglitazone was administrated at a high dose for 6 months, it reduced hyperinsulinemia as reflected by a reduced basal (steady-state) insulin concentration Ib and the insulin response to a glucose load, improved β-cell function as reflected by decreased second-phase post-hepatic insulin delivery to glucose Ø2, and reduced insulin resistance as reflected by increased insulin sensitivity to glucose disposal Si, without affecting glucose tolerance as reflected by an unchanged rate of glucose utilization Kg or insulin-independent glucose disposal Sg. The reductions in Ib and Ø2 and the increases in Si in WHHL rabbits treated with a high dose of troglitazone were greater (p<0.05) than those observed in WHHL rabbits treated with a low dose of troglitazone, as assessed by a two-way repeated measures analysis of variance and the Wilcoxon-Mann-Whitney test. Conclusion: In WHHL rabbits, troglitazone dose-dependently reduced hyperinsulinemia, improved β-cell function, and increased insulin sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kumar S, Boulton AJ, Beck Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group [published erratum appears in Diabetologia 1996 Oct;39(10):1245]. Diabetologia. 1996; 39: 701–709.

    Article  PubMed  CAS  Google Scholar 

  2. Prigeon RL, Kahn SE, Porte D, Jr. Effect of troglitazone on β-cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 1998; 83: 819–823.

    Article  PubMed  CAS  Google Scholar 

  3. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992; 15: 193–203.

    Article  PubMed  CAS  Google Scholar 

  4. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994; 43: 1435–1439.

    Article  PubMed  CAS  Google Scholar 

  5. Zhang B, Saku K, Arakawa K. Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. Metabolism. 1997; 46: 273–281.

    Article  PubMed  CAS  Google Scholar 

  6. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998; 273: 3547–3550.

    Article  PubMed  CAS  Google Scholar 

  7. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996; 45: 1572–1579.

    Article  PubMed  CAS  Google Scholar 

  8. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997; 100: 530–537.

    Article  PubMed  CAS  Google Scholar 

  9. Iwamoto Y, Kuzuya T., Matsuda A, Awata T, Kumakura S, Inooka G, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991; 14: 1083–1086.

    Article  PubMed  CAS  Google Scholar 

  10. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996; 19: 151–156.

    Article  PubMed  CAS  Google Scholar 

  11. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [see comments]. N Engl J Med. 1998; 338: 867–872.

    Article  PubMed  CAS  Google Scholar 

  12. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group [see comments]. N Engl J Med. 1998; 338: 861–866.

    Article  PubMed  CAS  Google Scholar 

  13. Zhang B, Saku K, Hirata K, Liu R, Tateishi K, Shiomi M, et al. Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril. Metabolism. 1994; 43: 360–366.

    Article  PubMed  CAS  Google Scholar 

  14. Zhang B, Saku K, Hirata K, Liu R, Tateishi K, Yamamoto K, et al. Insulin resistance observed in WHHL rabbits. Atherosclerosis. 1991; 91: 277–278.

    Article  PubMed  CAS  Google Scholar 

  15. SAS Procedures Guide, Version 6, Third Edition. Cary, NC: SAS Institute Inc.; 1990: 209–634

    Google Scholar 

  16. SAS/STAT User’s Guide, Version 6, Fourth Edition, Volume 2. Cary, NC: SAS Institute Inc.; 1990: 891–1210

    Google Scholar 

  17. Abel ED, Ledingham JG. Impaired glucose tolerance in hypertension is associated with impaired insulin release independently of changes in insulin sensitivity. J Hypertens. 1994; 12: 1265–1273.

    Article  PubMed  CAS  Google Scholar 

  18. Kahn SE, Prigeon RL, McCulloch D, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993; 42: 1663–1672.

    Article  PubMed  CAS  Google Scholar 

  19. Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, et al. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia. 1995; 38: 24–30.

    Article  PubMed  CAS  Google Scholar 

  20. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 1991; 40: 1213–1218.

    Article  PubMed  CAS  Google Scholar 

  21. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C. Quantitative estimation of beta cell sensitivity to glucose in the intact organism. Diabetes. 1980; 29: 979–990.

    Article  PubMed  CAS  Google Scholar 

  22. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [letter; comment]. N Engl J Med. 1998; 338: 916–917.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Experimental Animals, Koube University School of Medicine, Koube, Japan

    Masashi Shiomi & Keijiro Saku

  2. Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan

    Hiroaki Tanaka

  3. Pharmacology and Molecular Biology Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan

    Yoshio Tsujita & Hiroyoshi Horikoshi

  4. Department of Internal Medicine, Fukuoka University, 7-45-1 Nanakuma Jonan-ku, 814-080, Fukuoka, Japan

    BO Zhang, Junru Mei & Ping Fan

Authors
  1. BO Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Shiomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroaki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junru Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ping Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Tsujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyoshi Horikoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keijiro Saku
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, B., Shiomi, M., Tanaka, H. et al. Effects of high-dose troglitazone on insulin sensitivity and β-cell function in watanabe heritable hyperlipidemic rabbits. Eur. J. Drug Metab. Pharmacokinet. 26, 185–192 (2001). https://doi.org/10.1007/BF03190395

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190395

Keywords

Search

Navigation